CoChat

The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease

Irvine, Katharine M., Wockner, Leesa F., Shanker, Mihir, Fagan, Kevin J., Horsfall, Leigh U., Fletcher, Linda M., Ungerer, Jacobus P. J., Pretorius, Carel J., Miller, Gregory C., Clouston, Andrew D., Lampe, Guy, Powell, Elizabeth E. · 2016 · Liver International
Cited by 86

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background and Aims: Current tools for risk stratification of chronic liver disease subjects are limited. We aimed to determine whether the serum‐based ELF (Enhanced Liver Fibrosis) test predicted liver‐related clinical outcomes, or progression to advanced liver disease, and to compare the performance of ELF to liver biopsy and non‐invasive algorithms. Methods: Three hundred patients with ELF scores assayed at the time of liver biopsy were followed up (median 6.1 years) for liver‐related clinical outcomes (n = 16) and clear evidence of progression to advanced fibrosis (n = 18), by review of medical records and clinical data. Results: Fourteen of 73 (19.2%) patients with ELF score indicative of advanced fibrosis (≥9.8, the manufacturer's cut‐off) had a liver‐related clinical outcome, compared to only two of 227 (<1%) patients with ELF score <9.8. In contrast, the simple scores APRI and FIB‐4 would only have predicted subsequent decompensation in six and four patients respectively. A unit increase in ELF score was associated with a 2.53‐fold increased risk of a liver‐related event (adjusted for age and stage of fibrosis). In patients without advanced fibrosis on biopsy at recruitment, 55% (10/18) with an ELF score ≥9.8 showed clear evidence of progression to advanced fibrosis (after an average 6 years), whereas only 3.5% of those with an ELF score <9.8 (8/207) progressed (average 14 years). In these subjects, a unit increase in ELF score was associated with a 4.34‐fold increased risk of progression. Conclusions: The ELF score is a valuable tool for risk stratification of patients with chronic liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.12896

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 86

Metadata

Authors
Irvine, K. M., Wockner, L. F., Shanker, M., Fagan, K. J., Horsfall, L. U., Fletcher, L. M., Ungerer, J. P. J., Pretorius, C. J., Miller, G. C., Clouston, A. D., Lampe, G., & Powell, E. E.
Venue
Liver International
Publisher
Wiley
Published
2015-08-28
Volume
36
Issue
3
Pages
370-377
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W1889367418
Cited by
86
References
4
FWCI
3.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. https://app.cochat.ai/papers/10.1111/liv.12896
The paper
Irvine, K. M., Wockner, L. F., Shanker, M., Fagan, K. J., Horsfall, L. U., Fletcher, L. M., Ungerer, J. P. J., Pretorius, C. J., Miller, G. C., Clouston, A. D., Lampe, G., & Powell, E. E. (2016). The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver International. https://doi.org/10.1111/liv.12896

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.